Literature DB >> 11479317

Pleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes.

D Hudrisier1, J Riond, H Mazarguil, J E Gairin.   

Abstract

The fate of viral glycopeptides as cytotoxic T lymphocyte (CTL) epitopes is unclear. We have dissected the mechanisms of antigen presentation and CTL recognition of the peptide GP392-400 (WLVTNGSYL) from the lymphocytic choriomeningitis virus (LCMV) and compared them with those of the previously reported GP92-101 antigen (CSANNSHHYI). Both GP392-400 and GP92-101 bear a glycosylation motif, are naturally N-glycosylated in the mature viral glycoproteins, bind to major histocompatibility complex H-2D(b) molecules, and are immunogenic. However, post-translational modifications differentially affected GP92-101 and GP392-400. Upon N-glycosylation or de-N-glycosylation, a marked decrease in major histocompatibility complex binding was observed for GP392-400 but not for GP92-101. Further, under its N-glycosylated or de-N-glycosylated form, GP392-400 then lost its initial ability to generate a CTL response in mice, whereas GP92-101 was still immunogenic under the same conditions. The genetically encoded form of GP392-400, which on the basis of its immunogenicity could still be presented with H-2D(b) during the course of LCMV infection, does not in fact appear at the surface of LCMV-infected cells. Our results show that post-translational modifications of viral glycopeptides can have pleiotropic effects on their presentation to and recognition by CTL that contribute to either creation of neo-epitopes or destruction of potential epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479317     DOI: 10.1074/jbc.M105974200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.

Authors:  Pamela A Norton; Stephan Menne; Gomathinayagam Sinnathamby; Lucy Betesh; Paul J Cote; Ramila Philip; Anand S Mehta; Bud C Tennant; Timothy M Block
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.

Authors:  Ida Hafstrand; Daniel Badia-Martinez; Benjamin John Josey; Melissa Norström; Jérémie Buratto; Sara Pellegrino; Adil Doganay Duru; Tatyana Sandalova; Adnane Achour
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

3.  Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?

Authors:  Alex Olvera; Samandhy Cedeño; Anuska Llano; Beatriz Mothe; Jorge Sanchez; Gemma Arsequell; Christian Brander
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

4.  Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas.

Authors:  Yanfei Xu; Sandra J Gendler; Alessandra Franco
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.